Actively Recruiting
Phase 1 Open-Label Study of MT-201 with Infliximab in Healthy Adults Evaluating Safety and Immune Response
Led by Mirador Therapeutics, Inc. · Updated on 2026-08-21
25
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase 1, open-label study to evaluate the safety, tolerability, pharmacokinetics, and immune response of a single dose of MT-201 given together with infliximab in healthy adults aged 19 to 55 years. This early-phase trial aims to understand how these drugs behave in the body and their safety profile when used together. Participants will receive a single dose of MT-201 alongside infliximab. The study involves one group where all participants receive this combined treatment. There is no placebo or comparison group, and the study is open-label, meaning both participants and researchers know what treatment is given. During the study, participants will be monitored for any side effects or adverse events for up to 8 weeks after dosing. Researchers will collect data on safety and immune responses to understand how the body reacts to the drugs. Participants must be in good health and will be followed closely throughout the study duration, which starts from dosing and continues through the 8-week safety observation period.
CONDITIONS
Brief Title
A Single-Dose Study of MT-201 and Concomitant Infliximab in Healthy Participants
Research Team
T
Toll-Free Number
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
